BioPharmSignal logoBioPharmSignal

Biotech News

Kura Oncology to Report First Quarter 2026 Financial Results

Kura Oncology (KURA)Kura OncologyEarnings

SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2026 financial results after the close of U.S.

Open original release

Related news

KURAKura Oncology2026-05-12 20:02 EST

Kura Oncology Reports First Quarter 2026 Financial Results

KURAKura Oncology2026-06-02 12:32 EST

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

ARGXArgenx2026-07-16 05:00 EST

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

RVMDRevolution Medicines2026-05-06 20:02 EST

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

View all latest news

Kura Oncology

Kura Oncology is a precision-oncology company focused on genetically defined cancers and targeted therapies. Its pipeline is centered on kinase biology and oncology differentiation.

Recent company news

KURAKura Oncology2026-06-03 10:53 EST

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

KURAKura Oncology2026-06-02 12:32 EST

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

KURAKura Oncology2026-05-26 10:02 EST

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

KURAKura Oncology2026-05-19 20:02 EST

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

KURAKura Oncology2026-05-12 20:02 EST

Kura Oncology Reports First Quarter 2026 Financial Results

Stock data

Close
10.15 USD
Market cap
796.31M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States